World's Best Scientists 2026 revealed!
A. van Oosterom

A. van Oosterom

A. van Oosterom publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where A. van Oosterom sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

A. van Oosterom D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where A. van Oosterom sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

Overview

A. van Oosterom was affiliated with KU Leuven in Belgium during their academic career. Their work contributed to various aspects of scientific research, though specific details about publications, research topics, and collaborations remain limited in the available data.

There are no recorded recent papers listed for A. van Oosterom, which means that details such as the titles, years of publication, and venues of their research articles are not provided. Similarly, there is no information about frequent co-authors or regular publication venues, so patterns of collaboration and common platforms for their work cannot be described.

The available data does not include any book publications, leaving their involvement in longer form academic writing or editorial projects undocumented. The scientist's main fields of study and subfields are also not specified, making it difficult to pinpoint the specific academic disciplines or specialized areas they focused on throughout their career.

Likewise, no main topics of work are recorded, so it is not possible to outline the subjects or problems that they explored or contributed to. No awards have been listed, so there is no documentation of formal recognition or distinctions granted to them during their professional life.

The absence of detailed information regarding these aspects indicates that A. van Oosterom either maintained a low profile in published records accessible to this dataset or their work is documented elsewhere without being aggregated here. The data confirms that they are deceased, concluding their body of work as historical rather than ongoing.

Best Publications

  • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

    George D Demetri;Allan T van Oosterom;Christopher R Garrett;Martin E Blackstein

  • Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial*

    Jaap Verweij;Paolo G. Casali;John Zalcberg;Axel LeCesne

  • Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924

    Cora N. Sternberg;P. H.M. De Mulder;J. H. Schornagel;C. Théodore

  • Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

    M. Van Glabbeke;A.T. van Oosterom;J.W. Oosterhuis;H. Mouridsen

  • 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

    S. Stroobants;J. Goeminne;M. Seegers;S. Dimitrijevic

  • Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

    J Verweij;A van Oosterom;J.-Y Blay;I Judson

  • Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

    C.N. Sternberg;P.H.M. de Mulder;J.H. Schornagel;C. Theodore

  • Outcomes of cancer treatment for technology assessment and cancer treatment guidelines

    John Fetting;Paul Anderson;Harrison Ball;John Benear

  • Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

    A. Le Cesne;J.Y. Blay;I. Judson;A. Van Oosterom

  • Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma : a study by the EORTC Soft Tissue and Bone Sarcoma Group

    Ian R Judson;John A Radford;Maggie A Harris;Jean-Yves Blay

  • On the numerical accuracy of the boundary element method (EEG application)

    J.W.H. Meijs;O.W. Weier;M.J. Peters;A. Van Oosterom

  • Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.

    J P Neijt;W W ten Bokkel Huinink;M E van der Burg;A T van Oosterom

  • A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup.

    V H Bramwell;M Burgers;R Sneath;R Souhami

  • The Solid Angle of a Plane Triangle

    A. Van Oosterom;J. Strackee

  • Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

    H Wildiers;G Guetens;G De Boeck;E Verbeken

  • Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients.

    L. Y. Dirix;P. B. Vermeulen;A. Pawinski;A. ProvÃ

  • Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

    F.A.L.M Eskens;H Dumez;R Hoekstra;A Perschl

  • Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.

    A. Le Cesne;I. Judson;D. Crowther;S. Rodenhuis

  • Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas

    Vivien H.C. Bramwell;H.T. Mouridsen;A. Santoro;G. Blackledge

  • RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA

    J.P. Neijt;M.E.L. Van Der Burg;R. Vriesendorp;A.C.M. Van Lindert

Frequent Co-Authors

Jaap Verweij
Jaap Verweij Erasmus University Rotterdam
Richard Sylvester
Richard Sylvester European Organisation for Research and Treatment of Cancer
Ian Judson
Ian Judson Institute of Cancer Research
Peter B. Vermeulen
Peter B. Vermeulen University of Antwerp
Jan B. Vermorken
Jan B. Vermorken University of Antwerp
Sophie D. Fosså
Sophie D. Fosså Oslo University Hospital
Sergio Pecorelli
Sergio Pecorelli University of Brescia
Armando Santoro
Armando Santoro Humanitas University
U.R. Tjaden
U.R. Tjaden Leiden University
Dick F. Stegeman
Dick F. Stegeman Radboud University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens doors to a variety of rewarding online healthcare degrees and career pathways. For students interested in medication and patient care, online pharmacy school programs provide a flexible option to pursue a career as a pharmacist without compromising on quality education.

The rise of technology in healthcare has also made health informatics a fast-growing field. Pursuing a degree in health informatics equips students to manage, analyze, and secure health data for hospitals and clinics.

For those interested in administrative roles, understanding how much is medical billing and coding school costs and what programs offer can lead to a steady and in-demand position managing billing and patient records.

Finally, aspiring advanced practice nurses can explore the cheapest np school options to become nurse practitioners through affordable accredited online programs. These paths offer flexibility and strong job prospects in the dynamic field of healthcare.

Best Scientists Citing A. van Oosterom

Recently Published Articles